Categories: CancerNewsNursing

Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis

NORTHAMPTON, MA / ACCESSWIRE / June 5, 2024 / Emma was a 28-year-old nursing student when she was diagnosed with triple-negative breast cancer. She had always wanted children and, once she learned that her treatment could affect her fertility, she found herself needing to make a quick family planning decision to pursue in vitro fertilization (IVF) and freeze her eggs.

“You think that you have time to have all these things happen, and you don’t,” says Emma. “Your life is put on hold and your future’s put on hold, and who knows if you even could have kids.”

According to the National Breast Cancer Foundation, about 9% of women diagnosed with breast cancer in the United States are younger than 45 years old. While surgery and radiation rarely affect fertility, women who undergo chemotherapy can experience immediate or long-term infertility if eggs become damaged or destroyed. Other cancer treatments, such as hormone therapy, aren’t known to cause infertility, but the treatment duration could interfere with the biological clock of childbearing years.

Gilead partners with various organizations that support people living with breast cancer. One such organization, the Young Survival Coalition (YSC), recognizes the unique needs of people of childbearing age and works with patients under 40 through nearly every facet of their cancer treatment journey.

“People may tell you to focus on treating your cancer first, but it’s important that you also consider life after cancer treatment and the impact of any treatment you may choose,” says Amanda Nixon, YSC’s Director of Community Engagement and Empowerment. She says her organization always recommends that younger women diagnosed with cancer seek a consultation from a fertility preservation expert if having biological children is of interest.

Watch the video above to learn about two women’s fertility journey.

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

Staff

Recent Posts

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

2 hours ago

Establishment Labs Submits to FDA for Approval of Motiva Implants in Breast Reconstruction

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

2 hours ago

Adia Nutrition Inc. Recaps Transformative 2025: Explosive Growth, Strategic Focus, and Path to Nasdaq Uplisting

Winter Park, Florida--(Newsfile Corp. - December 29, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a…

2 hours ago

Changing Healthcare Trajectories With Positive Experiences

DaVita works with others in under-resourced communities to offer individualized health engagements, break down mistrust…

2 hours ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its…

2 hours ago

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Contract Research Organization for the REGAL trial has informed the Company that 72 events have…

2 hours ago